Drug Discovery Today 2012 v.17 №23-24

London, UK.: Elsevier. — 92 p.Since its launch in 1996, Drug Discovery Today has been at the cutting edge of the science underpinning drug discovery and development. Drug Discovery Today delivers highly current reviews to the readers, not only addressing the rapid scientific developments in drug discovery associated technologies, but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.Contents:
Foundation.
Essential considerations for using protein–ligand structures in drug discovery.
Gregory L. Warren, Thanh D. Do, Brian P. Kelley, Anthony Nicholls and Stephen D. Warren.
Gene to screen.
Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics.
Maria D.F.S. Barbosa, Sandeep Kumar, Helen Loughrey and Satish K. Singh.
Informatics.
Applications of Connectivity Map in drug discovery and development.
Xiaoyan A. Qu and Deepak K. Rajpal.
Post screen.
Genetic causes of cerebral folate defi ciency: clinical, biochemical and therapeutic aspects.
Mercedes Serrano, Belén Pérez-Dueñas, Julio Montoya, Aida Ormazabal and Rafael Artuch.
New therapeutic approaches to treating hypertension in pregnancy.
Alfonso Mate, Carmen M. Vázquez, Andrea Leiva and Luis Sobrevía.
Platforms for high-throughput screening of Wnt/Frizzled antagonists.
Alexey Koval and Vladimir L. Katanaev.
Structural mass spectrometry in biologics discovery: advances and future trends.
Jingjie Mo, Adrienne A. Tymiak and Guodong Chen.